APC and colorectal carcinoma: Furthermore, the results indicated that an IDO1-regulated molecular pathway could possibly lead to abnormal expression of beta-catenin in the nucleus/cytoplasm of CRC patients with a low mutation rate of APC, suggesting that IDO1 is an interesting target for immunotherapy.